Journal of Medicinal Chemistry · 2016 · 57 citations · 39 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsDrug-receptor InteractionsLigand BindingLigand-based DesignPotency OptimizationReceptor PharmacologyStructure-activity Relationship AnalysisFunctional AssaysPain PharmacologyPharmacological ProfilingPharmacological ScreeningReceptor Binding Optimization
In this study, we describe the design and synthesis of new N 5 -substituted-2-(2-furanyl) thiazolo[5,4- d ]pyrimidine-5,7-diamines ( 2 – 18 ) and their pharmacological characterization as A 2A adenosine receptor (AR) antagonists by using in vitro and in vivo assays. In competition binding experiments two derivatives ( 13 and 14 ) emerged as outstanding ligands showing two different affinity values (KH and KL) for the hA 2A receptor with the high affinity KH value in the femtomolar range. The in vitro functional activity assays, performed by using cyclic AMP experiments, assessed that they behave as potent inverse agonists at the hA 2A AR. Compounds 13 and 14 were evaluated for their antinociceptive activity in acute experimental models of pain showing an effect equal to or greater than that of morphine. Overall, these novel inverse agonists might represent potential drug candidates for an alternative approach to the management of pain.
39
A2A adenosine receptor protects tumors from antitumor T cells
Akio Ohta, Elieser Gorelik, Simon J. Prasad et al. · Proceedings of the National Academy of Sciences · 2006 · 1K citations
Medicine, Immunology, Oncology +16
Structure of the adenosine A2A receptor bound to an engineered G protein
Byron Carpenter, Rony Nehmé, Tony Warne et al. · Nature · 2016 · 458 citations · Full text